Drug Profile
Colorectal cancer DNA vaccine - Cellectis/Karolinska Institute
Alternative Names: Carcinoembryonic antigen DNA vaccine - Cellectis/Karolinska Institute; tetwtCEA DNALatest Information Update: 02 Sep 2022
Price :
$50
*
At a glance
- Originator Cyto Pulse Sciences; Karolinska Institute
- Developer Cellectis; Karolinska Institute
- Class Cancer vaccines; DNA vaccines; Gene therapies
- Mechanism of Action Gene transference; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Colorectal cancer
Most Recent Events
- 18 Aug 2022 Karolinska University Hospital in collaboration with Cyto Pulse Sciences completes a phase II trial in Colorectal cancer in Sweden (Intradermal) (NCT01064375)
- 22 Sep 2015 Colorectal cancer DNA vaccine is still in phase I/II trials for Colorectal cancer in Sweden
- 06 Nov 2009 Preclinical trials in Colorectal cancer in Sweden (Parenteral)